{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-224238","form_type":"8-K","ticker":"RNA","cik":"0002093101","company_name":"Atrium Therapeutics, Inc.","filed_at":"2026-05-14T20:50:07+00:00","discovered_at":"2026-05-14T20:51:01.328912+00:00","generated_at":"2026-05-14T20:51:26.765105+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Atrium Therapeutics reports Q1 collaboration revenue $19.6M, driven by $15M BMS milestone; cash $267.8M","bullets":["Collaboration revenue $19.6M in Q1 2026, primarily a $15M milestone from BMS partnership.","R&D expenses $16.7M, G&A $20.3M; cash and equivalents $267.8M.","ATR 1072 IND submission planned for H2 2026; pre-IND discussions with FDA/Health Canada completed.","Company launched as independent public on Feb 27, 2026 after spin-off from Avidity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-224238","json":"https://secwatch.observer/filing/0001193125-26-224238.json","markdown":"https://secwatch.observer/filing/0001193125-26-224238.md","text":"https://secwatch.observer/filing/0001193125-26-224238.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526224238/0001193125-26-224238-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526224238/d82207d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:51:26.765105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb63b1238e6cd7125ce792a6e1dcbcc323049261","claim":"Atrium Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.","evidence_excerpt":"Exhibit 99.1 Atrium Therapeutics Reports First Quarter 2026 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2093101/000119312526224238/0001193125-26-224238-index.htm","confidence":0.66,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}